NeoGenomics Laboratories   Report issue

For profit Phase 2
Founded: Fort Myers FL United States (2002)

Organization Overview

First Clinical Trial
2017
NCT03308942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NeoGenomics | NeoGenomics Laboratories

Active Ingredients

Drugs in Phase 2 Trials (6)

Key: NeoGenomics Laboratories (2) Acquired (4)

carboplatin (paraplatin) (1 trial)

io102 (1 trial)

niraparib (zejula) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (2 trials)

pemetrexed (alimta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 6